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Changes in chlamydia prevalence over time: how to observe 
the unobserved 
The ways that widespread testing and treatment of 
sexually transmitted Chlamydia trachomatis infections 
affect the prevalence and incidence of infection at the 
population level are not easy to understand, and the 
difficulties are well documented.1 First, chlamydia is 
an infection, so the dynamics of transmission between 
infectious and susceptible individuals are given by 
a non-linear function. Second, chlamydia screening 
recommendations were introduced without randomised 
controlled trial evidence of the effects of screening 
on prevalence. Third, most chlamydia infections are 
asymptomatic, so no reliable signal in surveillance data 
exists that distinguishes between changes in incidence 
and testing. Fourth, yearly population-based prevalence 
surveys with adequate coverage and precision are 
financially unfeasible. 
To help interpret the real-world effects of widespread 
chlamydia testing, England has more comprehensive 
and complete surveillance data2 than most countries. 
And, by chance rather than design, the British National 
Surveys of Sexual Attitudes and Lifestyles (Natsal) 
measured C trachomatis prevalence in 1999–2001 
(Natsal-2; just before the National Chlamydia Screening 
Programme in England, [NCSP] started its roll out) 
and 2010–12 (Natsal-3; just after the NCSP achieved 
countrywide coverage).3 The essence of the dilemma is 
that point prevalence estimates in the two surveys were 
nearly identical—chlamydia prevalence in women aged 
18–24 years was 3·1% (95% CI 1·8–5·2) in Natsal-2 and 
3·2% (2·2–4·6) in Natsal-3—and CIs were compatible 
with a decrease or increase in prevalence. But complex 
transmission dynamic mathematical modelling studies 
had predicted that, with the levels of investment and 
test coverage that the NCSP achieved, chlamydia 
prevalence should have dropped measurably and 
sustainably by now.4  
In a model-based analysis, Joanna Lewis and Peter 
White5 aim to clarify what might have happened 
between, and since, Natsal-2 and Natsal-3. The 
advantages of their approach are that they use national 
data on chlamydia testing and diagnosis and they 
developed a mathematical model that represents the 
relationships between uninfected and infected groups 
of people, with a minimal level of complexity. The 
code for the model is available online, so anyone can 
reproduce the findings and explore the model further.  
The model does not make predictions but allows a 
post-hoc interpretation of what might have resulted in 
the inferred changes in prevalence year by year. Lewis and 
White5 propose that increasing chlamydia test coverage 
in the NCSP to more than 20% of men and more than 
40% of women by 2010 resulted in a reduction in 
chlamydia prevalence, which occurred between the 
Natsal-2 and Natsal-3 data collection periods. The 
model-estimated rebound in prevalence, from 2011 to 
2012, coincided with a decrease in chlamydia testing. 
The model probably does not include some essential 
processes. Sex differences in prevalence and incidence 
highlight important issues. Between 2000 and 2007, 
prevalence inferred by the model increased in men and 
decreased in women (based on the authors’ preferred 
estimates of testing). The data presentation, as year-
to-year changes, can be difficult to interpret. Using the 
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Figure: Model-estimated Chlamydia trachomatis incidence rates, 2000–15
Data are estimated from the model published by Lewis and White.5 Lines show median estimates and shading 
shows 95% credible intervals. Red shows estimates using maximum numbers and orange shows estimates using 
minimum numbers.
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published code to plot absolute chlamydia incidence 
rates, with the maximum testing and diagnosis 
estimates, the model output estimates that between 
2000 and 2007, chlamydia incidence rates increased by 
a factor of 2·04 (95% credible interval 1·92–2·14) in men 
aged 15–19 years and by a factor of 1·84 (1·76–1·91) 
in men aged 20–24 years (figure 1). Lewis and White5 
suggest that male sexual risk-taking behaviour increased 
during that period, but this explanation is not entirely 
convincing because the substantial changes that would 
be needed to result in such large changes in incidence 
should affect both men and women. Data from Natsal6 
and from the USA over the same period,7 did not find 
marked or sex-specific changes in behaviour. 
Increased test coverage but poorer targeting over time 
of people with chlamydia could also explain a negligible 
decrease in prevalence. The model assumes the same 
screening rate in uninfected and infected people, 
although people at higher risk of chlamydia infection are 
more likely to be tested.3,8,9 NCSP test coverage targets 
after full implementation resulted in more tests, but the 
diagnosis rate did not change, suggesting that tests were 
done disproportionately amongst uninfected people.10 
Thus, the model outputs are consistent with Natsal-2 
and Natsal-3 prevalence estimates but, to balance 
the increase in screening rates, the model estimates 
large increases in incidence in men and high absolute 
incidence in women. 
At the public health level, the model output suggests 
that large increases in chlamydia testing were compatible 
with a modest temporary reduction in chlamydia 
prevalence, well below expectations. Whether these 
changes represent good value for money can be debated.4 
Duration of infection might, as Lewis and White suggest, 
be a better indicator of programme performance than 
prevalence. However, adopting this measure depends 
on the reliability of model-estimated prevalence and 
incidence.
Lewis and White’s study5 highlights important 
research priorities. Empirical estimates of C trachomatis 
incidence in the presence of widespread testing would 
be very valuable. Further mathematical modelling 
studies should investigate reasons for the gap between 
model-predicted and observed reductions in chlamydia 
prevalence, including the effects of differential testing 
according to infection status. And, a fourth Natsal is 
needed to provide the next estimates of C trachomatis 
prevalence and of sexual behaviour in Britain. National 
chlamydia control strategies need to be informed by 
sound evidence of effectiveness and optimal chlamydia 
case management. The search for robust indicators to 
monitor the dynamics of C trachomatis during screening 
interventions continues.
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